

Table I. *Patient characteristics.*

	FGFR2-negative (n=8)	FGFR2-positive (n=14)	<i>p</i> -Value
Sex (male)	7 (87.5%)	11 (78.6%)	0.59
Age	71.8 (\pm 3.0)	73.8 (\pm 2.3)	0.59
HER2 score=3	5 (62.5%)	11 (78.6%)	0.42
Tumor type 3 or 4	6 (75.0%)	6 (42.9%)	0.14
Tumor location (U/M/L)	2/5/1 (25.0/62.5/12.5%)	4/4/6 (28.6/28.6/42.9%)	0.21
Tumor differentiation (por-sig)	2 (25.0%)	1 (7.1%)	0.25
Stage IV ^a (before the treatment)	5 (62.5%)	9 (64.3%)	0.93
Postoperative recurrence (+)	3 (37.5%)	5 (35.7%)	0.93
Gastrectomy (+)	6 (75.0%)	6 (42.9%)	0.14
CEA (ng/ml)	14.6 (\pm 72.8)	98.9 (\pm 55.0)	0.37
CA19-9 (U/ml)	261.3 (\pm 109.2)	177.4 (\pm 82.5)	0.55

Values are in n (%) or mean (\pm standard deviation). ^aThe 8th edition of the International Union Against Cancer (UICC) tumor-node-metastasis (TNM) classification (17). CEA, Carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9.